Skip to main content

Table 2 Cost-effectiveness of antibiotics for treatment of cSSSI patients

From: Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia

Treatment strategy Total cost (USD) Incremental cost (USD) Total LY LY saveda ICER per LY saved
Vancomycin 15,254   7.52   
SXT/rifampicin 13,419 -1836 7.68 0.16 Dominant
Linezolid 16,387 1133 7.92 0.40 2833
Tedizolid 17,353 2099 7.90 0.38 5523
Daptomycin 17,238 1984 7.84 0.32 6200
Ceftaroline 17,971 2717 7.82 0.30 9057
  1. cSSSI complicated skin and soft structure infection, USD US dollar, LY life-years, ICER incremental cost-effectiveness ratio, SXT trimethoprim/sulfamethoxazole
  2. aCalculated as the average cost per patient and the average number of LY per patient in this strategy minus those of the treatment of vancomycin